- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.01. | Climb Bio advances clinical trials with first patients dosed in key studies | 1 | Investing.com | ||
| 08.01. | Climb Bio, Inc.: Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026 | 1.204 | GlobeNewswire (Europe) | First patients dosed in budoprutug PrisMN Phase 2 trial in pMN, with initial data expected second half 2026 Dosing ongoing in budoprutug Phase 1b/2a trial in ITP and Phase 1b trial in SLE; achieved... ► Artikel lesen | |
| 08.01. | Climb Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 02.01. | Alumis wirft Climb Bio Vertragsbruch wegen verweigerter Meilensteinzahlung vor | 10 | Investing.com Deutsch | ||
| CLIMB BIO Aktie jetzt für 0€ handeln | |||||
| 31.12.25 | Climb Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.12.25 | Freedom Capital Markets initiates Buy rating on Climb Bio stock with $9 target | 2 | Investing.com | ||
| 18.12.25 | H.C. Wainwright hebt Kursziel für Climb Bio wegen Budoprutug-Fortschritten auf 11 US-Dollar an | 3 | Investing.com Deutsch | ||
| 18.12.25 | H.C. Wainwright raises Climb Bio stock price target to $11 on budoprutug progress | 2 | Investing.com | ||
| 11.12.25 | Climb Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.11.25 | Climb Bio, Inc.: Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 5 | GlobeNewswire (USA) | ||
| 06.11.25 | Climb Bio, Inc.: Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates | 141 | GlobeNewswire (Europe) | PrisMN Phase 2 trial of budoprutug in Primary Membranous Nephropathy (pMN) initiated Phase 1 trial of budoprutug subcutaneous formulation initiated, with initial data expected in H1 2026 Clinical... ► Artikel lesen | |
| 06.11.25 | Climb Bio, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 06.11.25 | Climb Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.10.25 | Climb Bio, Inc.: Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy | 271 | GlobeNewswire (Europe) | WELLESLEY HILLS, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced... ► Artikel lesen | |
| 17.10.25 | Climb Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.10.25 | Climb Bio, Inc.: Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025 | 1 | GlobeNewswire (USA) | ||
| 16.10.25 | Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity | 1 | Benzinga.com | ||
| 16.10.25 | William Blair initiates coverage on Climb Bio stock with Outperform rating | 1 | Investing.com | ||
| 01.10.25 | Climb Bio beruft Susan Altschuller zur neuen Finanzvorständin | 3 | Investing.com Deutsch | ||
| 01.10.25 | Climb Bio taps Susan Altschuller as CFO | 1 | Seeking Alpha |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 95,80 | -0,21 % | Pharma- und Biotech-Aktien 2026: Bayer und BioNTech geben Gas, Bioxyne vor Durchbruch? | ||
| EVOTEC | 6,218 | -0,80 % | Puma-Übernahme wird konkreter! Als nächstes Evotec und Silver Viper Aktien kaufen? | Schon länger gibt es Übernahmespekulationen rund um Puma. Jetzt hat sich Anta 29 % am deutschen Sportartikelkonzern gesichert. Dafür zahlen die Chinesen 35 EUR je Aktie. An der Börse hält sich die Euphorie... ► Artikel lesen | |
| MEDIGENE | 0,046 | -3,39 % | Medigene: Gericht eröffnet Insolvenzverfahren | Bei Medigene geht die Insolvenz ihren Weg: Das zuständige Amtsgericht in München hat nach Angaben der Gesellschaft vom Freitag heute das Insolvenzverfahren über das Vermögen der Medigene AG sowie der... ► Artikel lesen | |
| MODERNA | 36,760 | -1,17 % | Moderna, Inc.: Dr. David Berman to Join Moderna as Chief Development Officer | CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / January 30, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that David Berman, M.D., Ph.D. has been appointed as the Company's Chief Development Officer... ► Artikel lesen | |
| VALNEVA | 3,894 | -0,36 % | Valneva im Wartemodus - gleich kommt das nächste Signal - nicht verpassen! | ||
| NOVAVAX | 7,437 | -0,34 % | NOVAVAX INC: Schwäche mit Signalwirkung | ||
| ILLUMINA | 122,04 | -0,08 % | Illumina, Inc.: Illumina completes acquisition of SomaLogic from Standard BioTools Inc. | Deeply expands leadership in proteomics and multiomicsCombined capabilities bring high scalability, flexibility, and affordability into protein analysis Combination leverages SomaScan with Illumina's... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 626,80 | +0,16 % | Regeneron Pharmaceuticals Inc Bottom Line Retreats In Q4 | WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals Inc (REGN) announced a profit for fourth quarter that Drops, from the same period last yearThe company's earnings totaled $844.6 million, or... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,370 | 0,00 % | INOVIO PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| VIKING THERAPEUTICS | 24,780 | +1,02 % | Eli Lilly or Viking Therapeutics: Which Stock Is More Likely to be a Millionaire-Maker? | ||
| BAVARIAN NORDIC | 25,810 | +0,47 % | Bavarian Nordic A/S: Bavarian Nordic - Transactions in Connection with Share Buy-Back Program | ||
| INTELLIA THERAPEUTICS | 11,105 | +0,14 % | Weekly Buzz: Intellia Gets FDA Nod For ATTRv-PN Trial; Aprea's APR-1051 Paces; CALC Halts KOURAGE | SOUTH SAN FRANCISCO (dpa-AFX) - This week's biotech landscape features key FDA approvals, clinical holds and go-aheads, trial discontinuations, and clinical trial data readouts across key therapeutic... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,420 | +0,96 % | Unheilbar wird therapierbar: Diese Nano-Biotech-Aktie vor dem Durchbruch! | ||
| MICROBOT MEDICAL | 1,592 | +4,53 % | Microbot Medical Inc.: Microbot Medical Receives First Patent in Japan as it Continues to Broaden its Global Intellectual Property Portfolio | Commercial Focus Remains on U.S. Market as it Continues to Explore Certain Global Markets that Accept FDA Cleared Devices Protecting its Innovative Technology Remains a Priority and Momentum Increasing... ► Artikel lesen | |
| IMMUNITYBIO | 5,298 | +0,23 % | ImmunityBio (IBRX) Sheds 4% on Profit-Taking After 14-Day Run |
Das Unternehmen CLIMB BIO INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 4,470 Euro und damit -6,49 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CLIMB BIO INC finden Sie auf Wallstreet Online.